Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 68 Publications

11 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NXLXTlB1S3m2b4TvfIlkKEG|c3H5 M1WzUFQ5KGh? NGjjPINFVVOR NHqzTlREgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN M1qxNlIyPTd{NUi5
BAF3 MUTDfZRwfG:6aXOgRZN{[Xl? MnywOFghcA>? M4PpS2ROW09? M4PlRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= NEH5XYIzOTV5MkW4PS=>
BAF3 MX7DfZRwfG:6aXOgRZN{[Xl? M2q0OVQ5KGh? MoK5SG1UVw>? NEnIXWJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtid3n0bEBKSzVyIH;mJFAvOjhizszN NGfTNZEzOTV5MkW4PS=>
Kelly NHjnfo1EgXSxdH;4bYMhSXO|YYm= NFfhOXhFVVOR M{fRfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN M2r4S|IyPTd{NUi5
SH-SY5Y NWrX[XpSS3m2b4TvfIlkKEG|c3H5 NV\oNFlwTE2VTx?= NInzWYFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO MUCyNVU4OjV6OR?=
SMS-KCN NWLpTHBNS3m2b4TvfIlkKEG|c3H5 MVrEUXNQ NXHBRZJkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? MXmyNVU4OjV6OR?=
BAF3 NUe2dWZmS3m2b4TvfIlkKEG|c3H5 MlPiOFghcA>? NGWxVVVFVVOR MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1? M1SydlIyPTd{NUi5
3T3 MXLGeY5kfGmxbjDBd5NigQ>? NYLzZolQOSCq MVvEUXNQ NWnLfpNkUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP NYXac5dDOjF6MUK0NVQ>
3T3-E MoDBSpVv[3Srb36gRZN{[Xl? NIfBdlYyKGh? M2jXVGROW09? MlPxTY5pcWKrdHnvckBw\iCWSVWyJIF{e2W|c3XkJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjR2ODFOwG0> Mn;GNlE5OTJ2MUS=
A549 M4LBT2tqdmG|ZTDBd5NigQ>? MXmxJIg> Mm[0SG1UVw>? M3nWTmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> Mkm3NlE5OTJ2MUS=
BAF3-BCL M3KzOmZ2dmO2aX;uJGF{e2G7 NX7oW4VoOSCq MlzuSG1UVw>? MUPJcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO MmDnNlE5OTJ2MUS=
HEK293 MYTGeY5kfGmxbjDBd5NigQ>? NWLJU3NiOSCq NYfuemF6TE2VTx?= NUjTbllmUW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= M2fiXFIyQDF{NEG0
HEK293 NWr4[|FQTnWwY4Tpc44hSXO|YYm= NFXPSHgyKGh? M2DX[WROW09? MkC1TY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO NGrmV5czOThzMkSxOC=>
Jurkat MXvGeY5kfGmxbjDBd5NigQ>? MWGxJIg> M{PFZWROW09? MmrHTY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? NYrx[oJVOjF6MUK0NVQ>
KARPAS299 MmHiT4lv[XOnIFHzd4F6 MmPUNUBp MWfEUXNQ MoH5TY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NWrZU4ZCOjF6MUK0NVQ>
PAE Mn3ySpVv[3Srb36gRZN{[Xl? MmrMNUBp MmLZSG1UVw>? M4f0NWlvcGmkaYTpc44hd2ZiVGLLRkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6zPVkh|ryP NVvleY5[OjF6MUK0NVQ>
BAF3 M1nFWWZ2dmO2aX;uJGF{e2G7 MUmyMVMh\A>? MXHEUXNQ MYrJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN MU[yN|c1OjJ3Mh?=
KARPAS299 NVLNUXo6S3m2b4TvfIlkKEG|c3H5 M{PlbFIuOyCm NWjJbppsTE2VTx?= M2PVd2lEPTB;MD6wOlQzKM7:TR?= NWjvU3U4OjN5NEKyOVI>
EBC1 M3Xoemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5WVM4OiCq MX7EUXNQ M{Hr[2lEPTB;MD6wNlMh|ryP NWm5cZcxOjN7OUOzNlg>
HCT116 M1K1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvoNHUyPzJiaB?= MWHEUXNQ MmTPTWM2OD1zND64NkDPxE1? MY[yN|k6OzN{OB?=
MCF7 NELvTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfqdFdMPzJiaB?= NY\HenF5TE2VTx?= NXvTTGtHUUN3ME25MlU5KM7:TR?= Ml7uNlM6QTN|Mki=
MDA-MB-231 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TnT|czKGh? NEnDZWdFVVOR MkjDTWM2OD1zMD64JO69VQ>? Mn\aNlM6QTN|Mki=
MKN45 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3DWJBHPzJiaB?= NVvQTJBvTE2VTx?= MUPJR|UxRTBwMEGzJO69VQ>? NF35TokzOzl7M{OyPC=>
NCI-H441 NUXGb2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp M2PSZWROW09? M3HFTGlEPTB;MUeuNlUh|ryP MkC3NlM6QTN|Mki=
NCI-H661 NH6yd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDyO|IhcA>? MVrEUXNQ NVnwcIJqUUN3ME2xNU41PyEQvF2= MVeyN|k6OzN{OB?=
SK-MEL-28 NHXzVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXHU4g4PzJiaB?= NEDRdGRFVVOR NEi3SFFKSzVyPUGwMlk4KM7:TR?= NHywZo4zOzl7M{OyPC=>
SKOV3 M12yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\1b3g4OiCq MoDrSG1UVw>? NXKx[FZmUUN3ME2xNk45PSEQvF2= MWKyN|k6OzN{OB?=
SNU5 NULwNGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV23NkBp NXexSlJsTE2VTx?= MljMTWM2OD1yLkCxOkDPxE1? M3fIZlI{QTl|M{K4
NCI-H2228 NIGyVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXi3NkBp MYLEUXNQ NH;YNFZKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMUig{txO MVKyOFQ{OjlyOR?=
NCI-H3122 NYW3OXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp M{TpW2ROW09? NYn0eoFyUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? MoT1NlQ1OzJ7MEm=
NCI-H3122 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXsOmhIPzJiaB?= Ml;0SG1UVw>? MXLJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= NGHuTVgzPDR|MkmwPS=>
NCI-H3122 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTCV2xrPzJiaB?= MnHOSG1UVw>? MVvJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= M4rROFI1PDN{OUC5
NIH-3T3 M1zqO2tqdmG|ZTDBd5NigQ>? MVOxJIg> NEXtVWdFVVOR M4rodmlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP M37aSFI1PDN{OUC5
NIH-3T3 MX7LbY5ie2ViQYPzZZk> M4jBZVEhcA>? M1vqbGROW09? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0> NHrLTZkzPDR|MkmwPS=>
NIH-3T3 Mm\RT4lv[XOnIFHzd4F6 NH3rSY8yKGh? Mo\mSG1UVw>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZ{NjFOwG0> Mn;NNlQ1OzJ7MEm=
NIH-3T3 NVu4W3FFU2mwYYPlJGF{e2G7 NFrDOmgyKGh? Mnu4SG1UVw>? Ml7UTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC56NEOg{txO M1mxTlI1PDN{OUC5
NIH-3T3 MoTBT4lv[XOnIFHzd4F6 M2PVVlEhcA>? NVnvUFF7TE2VTx?= NEPnNlJKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkCyOkDPxE1? NHLR[3gzPDR|MkmwPS=>
BAF3 M3zEbmZ2dmO2aX;uJGF{e2G7 M3rEbVczKGh? MYPEUXNQ NYPoWpM{UW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? MV2yOFQ3QDZ|Mh?=
BAF3 NYPzXllMS3m2b4TvfIlkKEG|c3H5 MWi3NkBp M1:0cmROW09? NGHJcYxKSzVyPUCuPVgh|ryP M{XGSVI1PDZ6NkOy
NIH-3T3 NUHBTHJZU2mwYYPlJGF{e2G7 NYrlSGk1OSCq NFr4[YRKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1? NXrkN4NmOjR6MUmxNVY>
NIH-3T3 NY\NcW1rU2mwYYPlJGF{e2G7 M1X4SVEhcA>? MmPDTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC52N{ig{txO M3fmNFI1QDF7MUG2
NIH-3T3 MWLLbY5ie2ViQYPzZZk> M3zvR|EhcA>? NVf5PW5XUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP NEPuU2YzPDhzOUGxOi=>
NIH-3T3 M13M[GtqdmG|ZTDBd5NigQ>? M2e4OFEhcA>? NVvTV205UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= NUPIR5ZHOjR6MUmxNVY>
KARPAS299 Ml3sT4lv[XOnIFHzd4F6 NVLQc5p[QTBibXnu NFLiXG5FVVOR MnjvTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NH3NRpozPDlyMEe1NC=>
MKN 45 NF3nNYJMcW6jc3WgRZN{[Xl? M1fZTlEhcA>? NFTjcXJFVVOR NF7mZ2xKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1? MUiyOFkxODd3MB?=
A549 MkTmR5l1d3SxeHnjJGF{e2G7 MlP4OFghcA>? Mk\vSG1UVw>? M{PrdmlEPTBib3[gOE4xQDRizszN NWjNSVVTOjR7MEC4N|A>
NCI-H1975 NHq1XWREgXSxdH;4bYMhSXO|YYm= MWW0PEBp M2TCZ2ROW09? MlLoTWM2OCCxZjC3MlU2OSEQvF2= MmDVNlQ6ODB6M{C=
NCI-H1993 NXHjTJkyS3m2b4TvfIlkKEG|c3H5 MUO0PEBp MmDsSG1UVw>? M3HtOWlEPTBib3[gNE4xPjFizszN NIr2WmgzPDlyMEizNC=>
NCI-H1993 NFXqPYdCeG:2b4Ppd{BCe3OjeR?= MYOxJO69VQ>? MnTONlQhcA>? M2jIOmROW09? MWLkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| MX:yOFkxODh|MB?=
NIH-3T3 NYSzVJBoS3m2b4TvfIlkKEG|c3H5 NFL2VHU1QCCq M4XBWWROW09? MYTJR|UxKG:oIECuN|Y1KM7:TR?= NILF[HkzPDlyMEizNC=>
EBC1 NIrzbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\MUHR1PzJiaB?= NGLBdIZFVVOR NEKxV4VKSzVyIH;mJFAvODB4OTFOwG0> MlrONlQ6ODB6M{G=
KARPAS299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nZcVczKGh? MmPUSG1UVw>? MlexTWM2OCCxZjCwMlIh|ryP MX6yOFkxODh|MR?=
NB1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml63TWM2OD17MT65PEBvVQ>? MmHGV2FPT0WU
NCI-SNU-5 NYPx[YJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPDSoR3UUN3ME2xNFUvPzVibl2= M2LmfXNCVkeHUh?=
SR M1\rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfiTWM2OD1zMk[uN|Ehdk1? MkHtV2FPT0WU
SF539 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTWdItKSzVyPUKwOE4zPCCwTR?= NEi0TmxUSU6JRWK=
SU-DHL-1 M2H3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTTWM2OD1|M{[uPFIhdk1? NV\HSVFlW0GQR1XS
SCC-3 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN3Nj63OkBvVQ>? MWDTRW5ITVJ?
DEL NVrOPYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O5ZmlEPTB;M{[5Mlkhdk1? NFr6OIRUSU6JRWK=
CTV-1 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTV7Nj60PEBvVQ>? M{PqXXNCVkeHUh?=
EM-2 M4\QXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXTTWM2OD14MEGuN|Qhdk1? NXi4cHhYW0GQR1XS
MHH-CALL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXXOnJvUUN3ME22PFIvPTdibl2= MXjTRW5ITVJ?
KM12 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLuTWM2OD15ME[uPUBvVQ>? NUK5Om0zW0GQR1XS
KINGS-1 NHjQ[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXEXW5KSzVyPUe0PU44PSCwTR?= M36xS3NCVkeHUh?=
MEG-01 M1\uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX5XXdKSzVyPUi1O{43PiCwTR?= MnLYV2FPT0WU
BV-173 NGPpcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwMEW5PVch|ryP MXLTRW5ITVJ?
LAMA-84 NUT4NIlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBS4xKSzVyPUGuN|gzQDJizszN MXHTRW5ITVJ?
KARPAS-299 NIr2cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrYN3dKSzVyPUGuOFA5PjFizszN NF\sdY1USU6JRWK=
K-562 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HyemlEPTB;MT63NlI3QSEQvF2= M{TQZnNCVkeHUh?=
SK-LMS-1 NInjU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;acGtKSzVyPUGuO|Y5PjdizszN MmPPV2FPT0WU
MOLT-16 NYXFUWRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;BOGZyUUN3ME2xMlk2PTd3IN88US=> MnPlV2FPT0WU
CMK NXj5coc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwOU[xOVkh|ryP M2nEWHNCVkeHUh?=
ST486 NVTGfJZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKwSmxQUUN3ME2yMlQ{ODd|IN88US=> MmL2V2FPT0WU
CI-1 M2\oWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofxTWM2OD1{LkS5OlU6KM7:TR?= MVnTRW5ITVJ?
KP-N-RT-BM-1 M4C5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GyXmlEPTB;Mj63NFEzOiEQvF2= NEL4UWlUSU6JRWK=
ALL-PO M37TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILRXZVKSzVyPUOuNVgzODdizszN M2jSenNCVkeHUh?=
KS-1 M2XKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK5TWM2OD1|LkKxNlI2KM7:TR?= MkfLV2FPT0WU
Becker NUOwOnBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRwMkO5N{DPxE1? NYfKbpZ3W0GQR1XS
GDM-1 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwMkS2NVch|ryP M3zrNHNCVkeHUh?=
BC-1 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;HTWM2OD12LkS5Nlc4KM7:TR?= MlzzV2FPT0WU
NB14 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHoV2xEUUN3ME20Mlg{PTJ2IN88US=> MV7TRW5ITVJ?
NOS-1 NFnZR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjITWM2OD13LkOzPFc1KM7:TR?= NHe0eVBUSU6JRWK=
MZ1-PC M2P0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jzUmlEPTB;NT64NlE2OSEQvF2= MnTvV2FPT0WU
A498 NXftZnR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjab2dKSzVyPU[uNFg1PzNizszN MYjTRW5ITVJ?
EW-16 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS4TWM2OD14LkO3O|c{KM7:TR?= NEj4V5lUSU6JRWK=
NALM-6 NF7k[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwNkizPFch|ryP NILLNHNUSU6JRWK=
EB-3 M1T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnfWlEPTB;Nz6wO|I{OyEQvF2= NXL0VG1zW0GQR1XS
697 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;QTmlEPTB;OT6yOFMzQSEQvF2= NXO0Tpl{W0GQR1XS
Ramos-2G6-4C10 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDVeHh5UUN3ME25MlU6QDR{IN88US=> M{\S[XNCVkeHUh?=
KNS-81-FD NVL6S25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fDOGlEPTB;OT62PVY2OyEQvF2= MXnTRW5ITVJ?
HUTU-80 NUPHdoF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTkT2tKSzVyPUmuO|Q3PDJizszN NFznUGpUSU6JRWK=
LS-411N NUHGcG5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrDb3ZtUUN3ME2xNE4xPTZ5IN88US=> MnzBV2FPT0WU
RPMI-8402 NYG4RnZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7oZlNKSzVyPUGwMlEyPiEQvF2= MlnTV2FPT0WU
KU812 NW\jVI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFyLkK5PVEh|ryP MXzTRW5ITVJ?
EW-1 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zYOmlEPTB;MUCuOFQzPSEQvF2= NVm3V2NkW0GQR1XS
HC-1 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK4TWM2OD1zMD60PFQ1KM7:TR?= M3Ln[XNCVkeHUh?=
NB69 NXHBXZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjGcGRLUUN3ME2xNE42ODR|IN88US=> NVey[mJWW0GQR1XS
MFH-ino MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfyVJZnUUN3ME2xNE45OzB|IN88US=> NVz1NnBmW0GQR1XS
CCRF-CEM MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnxbXRKSzVyPUGxMlU6PyEQvF2= MnnqV2FPT0WU
SK-N-DZ MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK4b3ozUUN3ME2xNk4xPDN4IN88US=> MWLTRW5ITVJ?
NCI-H720 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjLN4VKSzVyPUGyMlE4ODVizszN MXfTRW5ITVJ?
HCC1187 NFj6enNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF{LkKwOFEh|ryP Mk\vV2FPT0WU
IST-SL2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn6U4lKSzVyPUGyMlQ5PzJizszN MnG3V2FPT0WU
KE-37 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{Lke5OlYh|ryP M3[ycHNCVkeHUh?=
HCC1599 NUi2UFdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT3dFVzUUN3ME2xNk46ODZ7IN88US=> MoHXV2FPT0WU
A4-Fuk M4DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD1zMj65OVg3KM7:TR?= MYDTRW5ITVJ?
NKM-1 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPiTWM2OD1zMz6yPVI2KM7:TR?= M3rLUXNCVkeHUh?=
BE-13 M4nscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLKbIlxUUN3ME2xN{44QTh7IN88US=> NVPEeHJPW0GQR1XS
MV-4-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2LkCzNlQh|ryP MkDSV2FPT0WU
OPM-2 NHvUZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W4eWlEPTB;MUSuOFA5PSEQvF2= NUP3OmJGW0GQR1XS
KARPAS-422 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rnNGlEPTB;MUSuOVEzPiEQvF2= MmDEV2FPT0WU
RPMI-8226 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF2Lki5NVUh|ryP MmTEV2FPT0WU
KARPAS-45 NVrqNlJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPCR29KSzVyPUG1Mlc4OTZizszN MnPrV2FPT0WU
SK-PN-DW NVGwUFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrTdXpKSzVyPUG1Mlg3OzFizszN NFHrcY9USU6JRWK=
LC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDae3JHUUN3ME2xOk4yPTB4IN88US=> MXrTRW5ITVJ?
NCI-H1648 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonFTWM2OD1zNj6yOVQh|ryP MYTTRW5ITVJ?
RL95-2 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGexNo1KSzVyPUG2MlM6PzhizszN MULTRW5ITVJ?
KNS-42 M3vMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDwTWM2OD1zNj63Nlc1KM7:TR?= NGSyOWVUSU6JRWK=
RPMI-6666 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr4ZY1KSzVyPUG2MlkzOTFizszN M3L3UXNCVkeHUh?=
SIG-M5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF5LkG5NFMh|ryP NIfyUFdUSU6JRWK=
VA-ES-BJ NInJdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;DTWM2OD1zNz63OFUyKM7:TR?= MYPTRW5ITVJ?
MONO-MAC-6 M4f6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\uTWM2OD1zNz65N|EzKM7:TR?= NH:5PHNUSU6JRWK=
LAN-6 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m4PGlEPTB;MUiuO|U2PyEQvF2= MWfTRW5ITVJ?
A388 M{\Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnZRoRXUUN3ME2xPU4{ODV7IN88US=> MkK3V2FPT0WU
SK-NEP-1 NHHxdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJyLkKxN|Ih|ryP Ml7sV2FPT0WU
TE-10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZV2lEPTB;MkCuOVIzOSEQvF2= M4LwW3NCVkeHUh?=
HL-60 NYWyb3dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LSc2lEPTB;MkCuPVA6QSEQvF2= MUDTRW5ITVJ?
MC116 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJzLkeyNlEh|ryP MV\TRW5ITVJ?
SW962 NIrpdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITBR4lKSzVyPUKxMlc6OTVizszN M3T2Z3NCVkeHUh?=
NOMO-1 M1nmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WxPWlEPTB;MkKuOlU3PCEQvF2= NHnSephUSU6JRWK=
CTB-1 NHKxbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD1{Mj64OlcyKM7:TR?= NYHHOGVGW0GQR1XS
MRK-nu-1 NX72ZWFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ{LkmwO|Qh|ryP MonnV2FPT0WU
GR-ST NGXIXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTHTWM2OD1{Mz63OkDPxE1? MUXTRW5ITVJ?
HH MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O2PWlEPTB;MkSuNFA{KM7:TR?= NVKxNHlVW0GQR1XS
NCI-H1963 M1X1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXLNoNKSzVyPUK0MlA4QDJizszN MnnoV2FPT0WU
QIMR-WIL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ2Lki3O|Ih|ryP MnTWV2FPT0WU
CGTH-W-1 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonYTWM2OD1{NT6wO|I{KM7:TR?= M1m3S3NCVkeHUh?=
LP-1 M1jCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ3Lk[1OVEh|ryP M{PGNHNCVkeHUh?=
NCI-H748 M2PIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvxZoROUUN3ME2yOk42OTN5IN88US=> M{\T[HNCVkeHUh?=
PF-382 NXXoOItVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn0TWM2OD1{Nz6yNlI{KM7:TR?= NUXxbZdUW0GQR1XS
ATN-1 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ5LkO3N|Ih|ryP NXy5UGdXW0GQR1XS
L-540 NED2NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\NfmVKSzVyPUK3MlY1PTlizszN NUnweVNDW0GQR1XS
LXF-289 NF\nbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q3fWlEPTB;MkeuO|UyQSEQvF2= MW\TRW5ITVJ?
LS-513 NYf5WnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLCOVdKSzVyPUK4MlE5ODdizszN MmPNV2FPT0WU
NCI-H1581 NH\FUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPqV49KSzVyPUOwMlM6PzZizszN NVPMeplRW0GQR1XS
ES6 M3HXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\mWlF1UUN3ME2zNE43QDl7IN88US=> Ml3nV2FPT0WU
SW982 M3;DNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS3TWM2OD1|MD64OVY3KM7:TR?= NV\RcotZW0GQR1XS
DOHH-2 M4Xnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG1WWxKSzVyPUOxMlU5QTNizszN MoT2V2FPT0WU
DB NH:z[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrkVnVKSzVyPUOzMlk1OzFizszN Mnz4V2FPT0WU
MPP-89 M{naeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLY[VFiUUN3ME2zOE4yPzV4IN88US=> MX\TRW5ITVJ?
LB831-BLC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnvd4dtUUN3ME2zOE42OTh2IN88US=> MnfPV2FPT0WU
NB5 NXzo[nA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPiTWM2OD1|ND64OVM2KM7:TR?= NIH6SJhUSU6JRWK=
GB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:1SGNzUUN3ME2zOU4xPDZ7IN88US=> MYjTRW5ITVJ?
TE-15 M3P1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXHO4o1UUN3ME2zOU4zOjN6IN88US=> MXvTRW5ITVJ?
LC4-1 NHThcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPKdlhKSzVyPUO1MlM5PDdizszN NVL1SFQ1W0GQR1XS
NCI-H747 NFjsd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHsXotKSzVyPUO2MlE{PjlizszN NX;kbVI1W0GQR1XS
NTERA-S-cl-D1 NXHiW|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\VUllPUUN3ME2zPE44OzR5IN88US=> NH62dGVUSU6JRWK=
SK-MM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPP[oNKSzVyPUSwMlEyPDZizszN NFS3VYlUSU6JRWK=
TGW NFLhUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRzLkC1OlMh|ryP NVP1PGJRW0GQR1XS
ONS-76 NI[yfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nMNGlEPTB;NEKuOFg5OyEQvF2= NUf5cFJYW0GQR1XS
CPC-N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nNHRVUUN3ME20Nk46QTdzIN88US=> Ml7ZV2FPT0WU
ES4 NVSzUmhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR2LkSxOVMh|ryP MX\TRW5ITVJ?
Daudi NF;VT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2joWWlEPTB;NEWuNFgzPyEQvF2= MmLxV2FPT0WU
MOLT-4 NYrIeGo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j3bmlEPTB;NEWuNFg2OyEQvF2= NXPtNJNlW0GQR1XS
HT-144 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLqTWM2OD12Nj63NlYh|ryP NHLuZ5FUSU6JRWK=
SW872 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTNTWM2OD12OD6xPVM{KM7:TR?= M4OxR3NCVkeHUh?=
D-283MED MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7BTm9MUUN3ME20PE4{PTR{IN88US=> NGXDSo1USU6JRWK=
NCI-H2126 NXfTWYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGiyWZBKSzVyPUS4Mlg1PzZizszN NVS1ZZQ4W0GQR1XS
NCI-SNU-16 M{DidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;OXWhKSzVyPUS5MlIyPDNizszN NEe2dGpUSU6JRWK=
CESS MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR7LkWwPFgh|ryP NFTIbVdUSU6JRWK=
A101D M3exdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnSN4QzUUN3ME20PU46PzN4IN88US=> NH\0cWJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID